Chardan upgraded Kodiak Sciences to Buy from Neutral with a $61 price target. \"Stellar results\" from GLOW2, supported by enthusiasm among key opinion leaders with whom the firm spoke to at a recent ARVO conference, confirm the viability of the new formulation of the drug and \"erase our doubts about its safety and efficacy profile,\" the analyst tells investors.
